Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its quarterly earnings data on Tuesday. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06, Zacks reports. During the same quarter in the previous year, the business posted ($0.24) earnings per share.

Acurx Pharmaceuticals Price Performance

ACXP stock opened at $1.77 on Friday. The business’s 50-day moving average is $1.96 and its two-hundred day moving average is $2.14. The firm has a market capitalization of $28.76 million, a P/E ratio of -1.62 and a beta of -1.73. Acurx Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $5.28.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Acurx Pharmaceuticals in a research note on Thursday.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.